AI Drug Discovery Company Isomorphic Labs Completes $5 Billion Series C Funding Round
On November 17 that, according to The Defiant, AI drug discovery company Isomorphic Labs has closed a $5 billion Series C funding round co-led by Greenoaks and Sequoia Capital, with Alphabet returning as an investor.
The company will leverage the capital to expand its drug design engine, IsoDDE, explore new areas of biology, and build the operational capabilities needed to advance candidate drugs into clinical trials. The financing will support both its proprietary drug programs and collaborative projects with pharmaceutical partners.
The company noted that its internal oncology and immunology programs, as well as collaborative initiatives, have yielded positive preclinical results. New investor Andreessen Horowitz, alongside existing backers such as Thrive Capital, GV, and Temasek, also participated in the round.